Marcus Chen, a CFA charterholder, learns from a public industry conference that Tidemark Pharma's CEO mentioned 'exciting developments in our pipeline.' Later that day, Marcus reads a publicly available FDA database showing Tidemark filed for Phase III approval. He combines these two pieces of information and concludes Tidemark will receive approval soon. He buys Tidemark shares. Has Marcus most likely violated Standard II(A)?